Tolstikov Vladimir
BERG, 500 Old Connecticut Path, Bldg. B, Framingham, MA 01701, USA.
Metabolites. 2016 Jul 8;6(3):20. doi: 10.3390/metabo6030020.
Metabolomics has emerged as an essential tool for studying metabolic processes, stratification of patients, as well as illuminating the fundamental metabolic alterations in disease onset, progression, or response to therapeutic intervention. Metabolomics materialized within the pharmaceutical industry as a standalone assay in toxicology and disease pathology and eventually evolved towards aiding in drug discovery and pre-clinical studies via supporting pharmacokinetic and pharmacodynamic characterization of a drug or a candidate. Recent progress in the field is illustrated by coining of the new term-Pharmacometabolomics. Integration of data from metabolomics with large-scale omics along with clinical, molecular, environmental and behavioral analysis has demonstrated the enhanced utility of deconstructing the complexity of health, disease, and pharmaceutical intervention(s), which further highlight it as an essential component of systems medicine. This review presents the current state and trend of metabolomics applications in pharmaceutical development, and highlights the importance and potential of clinical metabolomics as an essential part of multi-omics protocols that are directed towards shaping precision medicine and population health.
代谢组学已成为研究代谢过程、患者分层以及阐明疾病发生、发展或对治疗干预反应中基本代谢改变的重要工具。代谢组学在制药行业中作为毒理学和疾病病理学的独立检测方法得以实现，并最终通过支持药物或候选药物的药代动力学和药效学特征分析，朝着辅助药物发现和临床前研究的方向发展。该领域的最新进展体现在新术语“药物代谢组学”的出现。将代谢组学数据与大规模组学数据以及临床、分子、环境和行为分析相结合，已证明在解构健康、疾病和药物干预复杂性方面具有更高的效用，这进一步凸显了它作为系统医学重要组成部分的地位。本综述介绍了代谢组学在药物开发中的应用现状和趋势，并强调了临床代谢组学作为多组学方案重要组成部分的重要性和潜力，这些多组学方案旨在塑造精准医学和促进人群健康。
